% | $
Quotes you view appear here for quick access.

Atossa Genetics, Inc. Message Board

  • hofno2003 hofno2003 Sep 25, 2013 2:28 AM Flag

    Licencing Deal will be announced soon .....

    I think that the Co is working hard on its licencing options:
    - licencing for the development of a minimalinvasive local chemotherapeutic option based on Atossa IP
    - licencing ForeCyte for sale in countries where US approval is accepted and for CE marking in EU
    Thats the option to get money which is needed to support the expanding business in US. The CEO and CMO both hold about 60% of outstanding shares. I am sure that they will do everything possible NOT to dilute their own ownership share and that they will use all other available options to generate a cash inflow to the company.


    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The CEO and CMO ( ??? ) do not own 60% of the outstanding shares. They have spoken often about the micro-catheter they own from their Acuity acquisition a few years ago which they have said they are looking for a partner to take it into clinical trials. They have never spoken of EU licensing for Forecyte as Thermo Fisher and McKesson both have large foreign operations which could take care of foreign distribution. Your thoughts are welcome but your research should be a little better.

      • 1 Reply to innsbrooklad
      • Dear innsbrooklad,

        your thoughts are welcome.

        Per ownership statement November 7, 2012:
        - Mr. Quay, Steven, CEO, holds INDIRECT 4,275,580 shares
        - Mr. Quay, Steven, CEO, hold DIRECT 584,543 shares,
        both together about 30% of shares outstanding.

        Per ownership statement November 7, 2012:
        - Mr. Chen Shu-Chih, CMO (Chief Medical Officer) holds INDIRECT 4,275,580 shares;

        Both persons together control therefore about 60% of outstanding shares. This is a good insurance (poison pill) for an unfriendly and unadequate takeover and one reason to stay invested for the long run, even on essential higher PPS.

        It's alway good to dive deep for facts ......

        Mr. Quay repeatedly stated that ATOS is looking for a development partner to bring the chemotherapeutic treatment approach using Atossas IP (identifiyng the breast milk duct with abnormal cells and chemo treatment of this and only this duct by local chemo). This clinical trial can not be done by ATOS - and I am sure that Quay is looking for a partner and will be successfull sooner than later.


        Sentiment: Strong Buy

0.31+0.03(+11.55%)May 27 4:00 PMEDT